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The serine threonine kinase Akt is a core survival
factor that underlies a variety of human diseases.
Although regulatory phosphorylation and dephos-
phorylation have been well documented, the other
posttranslational mechanisms that modulate Akt
activity remain unclear. We show here that tetratrico-
peptide repeat domain 3 (TTC3) is an E3 ligase
that interacts with Akt. TTC3 contains a canonical
RING finger motif, a pair of tetratricopeptide motifs,
a putative Akt phosphorylation site, and nuclear
localization signals, and is encoded by a gene within
the Down syndrome (DS) critical region on chromo-
some 21. TTC3 is an Akt-specific E3 ligase that binds
to phosphorylated Akt and facilitates its ubiquitina-
tion and degradation within the nucleus. Moreover,
DS cells exhibit elevated TTC3 expression, reduced
phosphorylated Akt, and accumulation in the G2M
phase, which can be reversed by TTC3 siRNA or
Myr-Akt. Thus, interaction between TTC3 and Akt
may contribute to the clinical symptoms of DS.
INTRODUCTION
Serine threonine kinase Akt regulates diverse cellular processes,
including cellular survival, proliferation, cell cycles, cytoskeletal
organization, vesicle trafficking, glucose transport, and platelet
function. Deregulation and altered Akt activity underlies a vari-
ety of human diseases, including cancers, glucose intolerance,
schizophrenia, viral infections, and autoimmune diseases.
Therefore, the PI3K-Akt network provides an ideal target for
drug development.
Akt activation is regulated primarily by phosphorylation at
two critical sites: threonine 308/309/305 and serine 473/474/
472 (in Akt1/Akt2/Akt3, respectively). Phosphorylation of both
residues is required for maximum kinase activity. 3-Phosphoino-
sitide-dependent protein kinase (PDK) 1 has been identified as
a primary kinase that will phosphorylate Akt at Thr308. Kinases
that activate Ser473 are known as PDK2, which include
mitogen-activated protein kinase (MAPK)-activated protein800 Developmental Cell 17, 800–810, December 15, 2009 ª2009 Elskinase (PK)-2, integrin-linked kinase, p38 MAPK, PKCa,
PKCbII, rictor-mTOR complex (mTORC2), double-stranded
DNA-dependent PK, autophosphorylation, and ataxia telangiec-
tasia-mutated gene product (Brazil et al., 2004; Manning and
Cantley, 2007). Akt is also known to interact with various intracel-
lular molecules that modulate Akt activation and its downstream
signals (Du and Tsichlis, 2005; Noguchi et al., 2007). Recent
work has demonstrated that protein phosphatases, such as
pleckstrin homology (PH) domain leucine-rich repeat protein
phosphatase, can silence Akt by specifically dephosphorylating
the hydrophobic motif of Akt (reviewed by Manning and Cantley,
2007) The phosphorylation-dephosphorylation mechanisms are
thought to primarily control the PI3K-Akt signaling; however,
the involvement of ubiquitination-proteasomal pathways associ-
ated with Akt signaling have been reported (Dickey et al., 2008;
Facchinetti et al., 2008; Xiang et al., 2008).
Ubiquitin (Ub), a 76 residue protein, is covalently associated
with protein substrates. Protein ubiquitination is mediated
through three enzyme families (E1, E2, and E3). Ub is activated
first by a Ub-activating enzyme (E1) through an ATP-dependent
reaction to form an E1-thioesterlinkage, and the activated Ub is
transferred to a member of the Ub-conjugating enzyme E2
family. Ub-protein ligase (E3) mediates the transfer of Ub from
E2 to the substrate protein by promoting the formation of an
isopeptide bond between the Ub carboxyl terminus and specific
lysine side chains on the substrate (Hochstrasser, 2000; Pickart
and Eddins, 2004).
In addition to the cellular waste disposal machinery via the 26S
proteasome, ubiquitination can regulate wide varieties of cellular
functions, including cell surface-receptor turnover, gene tran-
scription, cell cycle transition, apoptosis, proliferation, DNA
repair, checkpoints, and differentiation (Pickart and Eddins,
2004). Thus, the activity of the Ub system is dependent on the
specificity of the E3 Ub ligases (Verma et al., 2004). To date,
a direct connection between the Akt and Ub pathways has not
been clearly observed, since an Akt-specific E3 ligase, which
can bind to Akt and induce ubiquitination of Akt, has not been
identified.
By using yeast two-hybrid systems with full-length human
Akt2 as bait, we found a stable interaction between the
tetratricopeptide (TPR) repeat domain 3 (TTC3) and Akt. TTC3,
which harbors a RING finger motif for Ub-protein ligase and
putative Akt phosphorylation motifs, is located at chromosomeevier Inc.
Figure 1. TTC3 Specifically Associates with
Akt in Mammalian Cells
(A) Diagram showing the structure and the
functional domains of Flag-tagged wild-type and
TTC3 subfragments in mammalian expression
vectors (N-Term, Int-, and C-Term TTC3) used in
the current study. C-Term, C-terminal fragment;
Int, internal fragment; N-Term, N-terminal fragment.
(B) Flag-tagged TTC3 interacted with HA-tagged
Akt1 (lane 1), Akt2 (lane 4), and Akt3 (lane 7) in
a coimmunoprecipitation assay. Similar amounts
of each Akt isoform were immunoprecipitated by
HA antibody.
(C) Using Hs52.Sk cells (Down syndrome-derived
skin fibroblast), in which TTC3 is endogenously
overexpressed, TTC3 coimmunoprecipitated with
endogenous Akt1, Akt2, and Akt3.
(D) Specificities of the Akt-TTC3 interaction were
demonstrated, since TTC3 did not interact with
PDK1 or PrKA by using transfected 293T cells
(lanes 4–6 and 7–9). Similar levels of Akt, PDK1,
and PrKA were immunoprecipitated by HA
antibody. Flag-TTC3 expression is shown in the
bottom panel as internal controls (C, control
antibody; F, anti-Flag antibody; HA, anti-HA
antibody).
(E and F) To define the domains of TTC3 that
interact with Akt, a series of Flag-tagged TTC3
subfragments (E) and HA-Akt (F) were generated.
Amino acids 491–1539 of TTC3 (Int-TTC3) were
the binding domain for Akt in coimmunoprecipita-
tion assays (lanes 7–9, [E]; Int-TTC3). The
C terminus of Akt is required for TTC3 interaction
(lanes 7–9, [F]).
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TTC3, an E3 Ligase for Akt21 within the Down syndrome (DS) critical region (DSCR)
(Antonarakis et al., 2004; Rachidi et al., 2000; Reeves et al.,
2001; Tsukahara et al., 1998). Here, we demonstrate that TTC3
is an Akt-specific E3 ligase that binds phosphorylated Akt and
can silence its activity via a proteasomal cascade. This finding
could underlie important clinical manifestations of DS, the
most common genetic disorder of humans.
RESULTS
TTC3 Is a Binding Partner for Akt
We identified two independent clones encoding a partial cDNA
of human TTC3 (aa 890–1100 and 870–1102) by using
human Akt2 as bait in yeast two-hybrid screening (Tsukahara
et al., 1998). TTC3 originally was identified as one of the candi-
date genes for DS located within the DSCR of human chromo-Developmental Cell 17, 800–810, Dsome 21 (Antonarakis et al., 2004;
Rachidi et al., 2000; Reeves et al.,
2001). The open reading frame for TTC3
is 2025 amino acids in length, and has
76% homology between humans and
mice. Identified motifs of TTC3 include
a pair of TPR motifs (Lamb et al., 1995),
nuclear localizing signals and the
canonical C-terminal H2-RING domainwith a short motif rich in cysteine and histidine residues (CEIC
HEVFKSKNVRVLKCGHKYHKGCFKQWLKGQSACPACQ) (Fig-
ure 1A).
Three Akt isoforms (Akt1, Akt2, and Akt3) are present in the
human genome, and are greater than 85% homologous at the
amino acid level. Using 293T cells, all three Akt isoforms, but
not PDK1 or PrKA, interacted with TTC3 (Figures 1B and 1D).
The interactions between endogenous TTC3 and the three
isoforms of Akt (Akt1, Akt2, or Akt3) were further confirmed in
coimmunoprecipitation experiments (Figure 1C).
To further define the interacting domains within TTC3 with Akt,
a series of TTC3 subfragments were generated in mammalian
expression vectors (see Figure 1A). Transfection of these vec-
tors into 293T cells demonstrated that the Int-TTC3 vector
(aa 491–1539 of TTC3) could mediate a stable interaction with
Akt during coimmunoprecipitation (Figure 1E).ecember 15, 2009 ª2009 Elsevier Inc. 801
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TTC3, an E3 Ligase for AktThe Akt protein possesses the N-terminal PH domain and the
C-terminal catalytic kinase domain. The interaction between
TTC3 and Akt was mediated primarily through the C-terminal
domain of Akt in coimmunoprecipitation assays (Figure 1F).
Since the initial TTC3:Akt interaction was identified by using
Akt2, we focused our investigation of the biological significance
of this interaction by using Akt2, unless specified.
TTC3 Is an E3 Ub Ligase for Akt
The TTC3 gene encodes canonical E3 RING finger motif at the
C-terminal end (see Figure 1A). One of the most remarkable
features of the Ub-conjugating pathway is the diversity of
substrate specificity, which is determined essentially by the E3
ligases. To determine whether TTC3 actually has Ub ligase
activity, we generated recombinant TTC3 protein (see Figure S1
availableonline) andperformed invitro ubiquitinationassays. First,
we examined the preference of TTC3 among the eight human E2
enzymes in the presence of E1. TTC3 was polyubiquitinated only
in the presence of Ubc4 or Ubc5C as E2 enzymes (Figure 2A).
Next, to examine the requirement of ATP, Ub, E2, and TTC3 for
the ubiquitination reaction, we performed in vitro ubiquitination
assays with various combinations in which one component
(ATP, Ub, E2, or TTC3) was missing from the reaction mixture.
Immunoblot analysis using an anti-Ub antibody revealed that
TTC3 exhibits ubiquitination activity only in the presence of E1,
E2 (Ubc5C), Ub, ATP, and TTC3 (Figure 2B). Furthermore, TTC3
preferentially polyubiquinated phosphorylated Akt compared
with unphosphorylated Akt (Figure 2C; also see Figures 3A–3D),
supporting the notion that TTC3 is acting as an E3 ligase for Akt.
Since TTC3 interacts specifically with Akt, we asked whether
TTC3-dependent ubiquitination is specific for Akt. Using 293T
cells transfected with wild-type TTC3 and HA-tagged human
Akt, we observed efficient polyubiquitinated Akt (Figure 2D, left
panel). Specificity of ubiquitination on Akt further confirmed
that TTC3 induced only ubiquitination of Akt (endogenous), but
not AK1 kinase (endogenous) or citron kinase (Figure 2D, right
panel, and data not shown). The TTC3 RING finger motif is
required for Akt ubiquitination, since wild-type TTC3 (but not
DRF-TTC3, which lacks the RING finger motif) induced ubiquiti-
nation (Figure 2E). Moreover, the binding-defectivemutant (DAB)
or N-terminal TTC3 exhibited significantly low levels of ubiquiti-
nation activity (Figure S2), which correlated well with decreased
Akt degradation (Figure S3). These results suggest that interac-
tion of the TTC3-Akt is important for biological function.
K48R-Ub, in which lysine 48 of Ub is mutated into arginine,
completely abolished efficient ubiquitination, demonstrating
that TTC3 conjugated with K48-linked polyubiquitin chain(s)
onto Akt (Figure 2F). Knockdown of TTC3 by siRNA failed to
induceAkt ubiquitination (Figure 2G). Furthermore, TTC3 induced
ubiquitination more efficiently on wild-type Akt compared with
T308A-S473A-Akt in an in vitro ubiquitination assay (Figure 2H).
TTC3 Preferentially Binds to Phosphorylated Akt
and Facilitates Its Proteasomal Degradation
Phosphorylation plays a key role in ubiquitination by E3 enzymes
and subsequent proteolysis (Gao and Karin, 2005; Hunter, 2007).
Therefore, we next verified the phosphorylation-dependent
interactions of TTC3 with Akt. The interaction between endoge-
nous Akt-TTC3 was augmented when Akt was activated/phos-802 Developmental Cell 17, 800–810, December 15, 2009 ª2009 Elsphorylated (Figure 3A). This finding correlated with efficient
ubiquitination of Akt in both cellular (Figure 3C) and in vitro
ubiquitination assays (see Figure 2C). Furthermore, TTC3 bound
to the phosphorylated Akt more efficiently compared with
nonphosphorylated Akt in a GST-pulldown assay (Figure 3B),
and in coimmunoprecipitation assays (Figure 3D).
Increasing amounts of TTC3-siRNA, but not control siRNA,
reduced the TTC3 expression in a dose-dependent manner
(Figure 3E). TTC3 expressions were correlated inversely with
phosphorylated Akt (Thr308 and Ser473) and phosphorylated
FKHR, without affecting MAPKs. In these experiments, total Akt
showed no increase with the addition of TTC3-siRNA, since only
a small fraction of Akt was phosphorylated. Furthermore, TTC3
induced Akt degradation via a proteasomal cascade when Akt
was activated by Myr-Akt (Figure 3F).
Phosphorylation of TTC3 at Ser378 Is Required
for Efficient Biological Function
Using Scansite (http://scansite.mit.edu/; Obenauer et al., 2003),
Ser378 of TTC3 (TPRSLSAP) was identified as a putative
phosphorylation site for Akt. Immunoprecipitation of Flag-
tagged TTC3 followed by immunoblotting and detection with
an anti-phospho Akt antibody indicated that Akt activation
induced phosphorylation of wild-type TTC3 (Figure 4A, top
panel, lane 5), but failed to induce phosphorylation of
S378A-TTC3 in Myr-Akt-transfected cells by anti-phospho Akt
substrate-specific immunoblot after Flag (TTC3) immunoprecip-
itation (Figure 4A). Analogous to this finding, DN-TTC3, which
also lacks S378 of TTC3, failed to be phosphorylated by Akt
(data not shown). In an in vitro Akt kinase assay, phosphorylation
of wild-type TTC3, but not S378A-TTC3 (Figure 4B), was
detected. We then performed an Akt-siRNA experiment to
suppress the endogenous expression of Akt and verify the levels
of phosphorylation of TTC3. The levels of TTC3 phosphorylation
detected by anti-Akt substrate antibody (cat. no. 9611; Cell
Signaling Technology) were diminished in intensity (Figure 4C).
Together, these observations support that TTC3 is a phosphory-
lation target of Akt both in an in vitro and in a cellular context,
although we cannot rule out the possibility that other kinases,
such as S6K, might be able to phosphorylate TTC3 S378 in vivo.
Functionally speaking, Ser378 appears to be important for the
regulation of TTC3’s biological activity. Cells transfected with
S378A-TTC3 or DRF-TTC3 demonstrated lower ubiquitination
action compared with wild-type TTC3 (Figure 4D). In addition,
wild-type TTC3, but not S378A-TTC3, could induce Akt degra-
dation in a time-dependent manner (Figure 4E). Wild-type
TTC3 could also induce mitochondrial membrane depolarization
more efficiently compared with S378A-TTC3 when measured by
rhodamine 123 (Rho123) transport (Figure 4F).
Akt is known to activate IKK, resulting in transactivation of
NFkB as one its antiapoptotic responses. In a luciferase reporter
assay, wild-type TTC3 inhibited NFkB transactivation more effi-
ciently compared with S378A-TTC3 (Figure 4G). Furthermore,
proliferation assays also indicated that wild-type TTC3 had
a higher level of antiproliferation activity compared with
S378A-TTC3 (Figures 4H and 6A). However, addition of Myr-Akt
could block this effect of TTC3 (Figures S4A–S4C). Together,
these results establish that Ser378 of TTC3 plays an important
role in Akt-dependent activities.evier Inc.
Figure 2. TTC3 Is an E3 Ub Ligase for Akt
(A) Since TTC3 contains a canonical E3 RING
finger motif, we first determined if TTC3 actually
has an Ub ligase activity. An in vitro ubiquitination
assay was performed using recombinant TTC3
(see Figure S1), together with recombinant rabbit
E1, recombinant human E2s, phosphocreatine
kinase, and bovine Ub and immunoblotted with
anti-Ub antibody. TTC3 was polyubiquitinated
only in the presence of Ubc4 or UbcH5C as E2
enzymes (lanes 5 and 8; Ubc4 andUbc5C, respec-
tively, [A]). Ub ligase chaperon-associated Ub
ligase protein with Ubc5C was used as a positive
control (PC).
(B) Next, we performed an in vitro ubiquitination
assay to evaluate the requirement of ATP, Ub,
and E2 (Ubc5C) for the TTC3 ubiquitination
activity. Efficient ubiquitination was achieved
only in the presence of TTC3 as an E3 ligase, but
lack of any other components (Ubc5C, Ub, or
ATP) achieved nondetectable levels of ubiquitina-
tion (lane 3).
(C) In in vitro Akt ubiquitination assays, TTC3
ubiquitinated the phosphorylated Akt much
more efficiently than the nonphosphorylated Akt
(compare lanes 7 and 4, active Akt versus inactive
Akt, respectively). Equal amounts of Akt were
used, shown by immunoblotting in the lower
panel. The levels of Akt phosphorylation were veri-
fied by immunoblotting as shown in Figure 3B.
(D) Left panel: efficient Akt polyubiquitination was
induced only in the cells transfected with Flag-
TTC3 and HA-Akt with His-Ub (lane 4). HA-Akt
(HA) or TTC3 expressions after immunoprecipita-
tion are shown in the lower panel (lanes 3–4). Right
panel: TTC3-induced ubiquitination was Akt
specific, since TTC3 solely induced ubiquitination
of Akt (lane 7), but not AK1 kinase (lane 6). The
HA-Akt and Flag-TTC3expression after immuno-
precipitation are shown (lower panels).
(E) Wild-type TTC3 or DRF-TTC3 (lacks RING
finger domain) with pCGN-HA-Ub (HA-tagged
Ub) was transfected into 293T cells. It is clear
that the C-terminal RING finger motif of TTC3
was required for efficient polyubiquitination of
Akt. An equal amount of Akt was immunoprecipi-
tated, shown by Akt immunoblot. The expressions
of TTC3 (Flag) are shown by immunoblot (lower
panel).
(F) TTC3 conjugated with K48-linked polyubiquitin chains on Akt, since only wild-type Ub, but not K48R-Ub, induced efficient ubiquitination. The expressions of
Akt after immunoprecipitation and the expression of TTC3 (Flag) are shown (lower panels).
(G) Suppression of endogenous TTC3 expression by siRNA (top panel) completely abolished efficient Akt ubiquitination (middle panel, TTC3-siRNA [lane 2] or
control siRNA-treated cells [lane 4], respectively). Equal amounts of Akt were immunoprecipitated (lower panel).
(H) In in vivo Ub assays, TTC3 preferentially ubiquitinated with wild-type Akt, but not T308A-S473A-Akt2, in which both threonine 308 and serine 473 were
substituted into alanine. Equal amounts of immunoprecipitated Akt or Flag-TTC3 expression were verified by immunoblotting (lower panels).
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TTC3, an E3 Ligase for AktTTC3 Associates with Akt and Induces
Polyubiquitination and Proteolytic Degradation
of Akt within the Nucleus
Since TTC3 contains a pair of ‘‘nuclear localization’’ signals (see
Figure 1A), and an activated Akt is known to translocate to the
nucleus (Andjelkovic et al., 1997), we next compared the levels
and the distribution of ubiquitination and phosphorylation of
Akt between the cytoplasmic (C) and nuclear (N) fractions.
TTC3 facilitated efficient polyubiquitination of endogenous Akt
(Figure 5A), and transfected Akt (Figure S5), within the nucleus.DevelopmeConsistently, nuclear Akt, which is phosphorylated, is degraded
more efficiently compared with the cytoplasmic Akt by TTC3 via
a proteasomal cascade (Figures 5B and 5C).
Confocal microscopy was utilized to further define the nuclear
colocalization of Akt with TTC3 by using a rabbit anti-TTC3
antibody (Figures S6A and S6B). During interphase, TTC3 was
observed to colocalize with Akt, primarily within the nucleus in
both NIH 3T3 cells and Hs52.Sk cells (DS skin fibroblast;
ATCC), in which TTC3 was endogenously expressed (Figures
5D, 5E, and 5G). Furthermore, TTC3 preferentially colocalizedntal Cell 17, 800–810, December 15, 2009 ª2009 Elsevier Inc. 803
Figure 3. TTC3 Preferentially Binds to
Phosphorylated Akt and Facilitates
Proteasomal Degradation
(A) NIH 3T3 cells were cultured in the presence or
absence of FBS to activate or inactivate Akt. The
interaction of endogenous TTC3 with Akt was
enhanced by serum stimulation, which induced
Akt activation (upper panel). Levels of expression
of phospho-Thr308Akt, pan-Akt, and endogenous
TTC3 are also shown.
(B) GST pulldown assays were performed using
active and inactive Akt (Upstate Biotech) recombi-
nant TTC3. Active Akt, but not inactive Akt,
interacted efficiently with GST-TTC3 (left panel,
lanes3and4, active and inactiveAkt, respectively).
Akt phosphorylations at Ser473 or Thr308 were
confirmed by immunoblotting (right panels).
(C) 293T cells were transfected with wild-type
TTC3 with pCGN-HA-Ub. PDGF stimulation,
known to activate Akt, induced efficient Akt
polyubiquitination (upper panel). Levels of Akt
expression (middlepanel) andphospho-Thr308Akt
(lower panel) after immunoprecipitation are shown.
(D) In coimmunoprecipitation assays, TTC3 prefer-
entially interacted with wild-type Akt, but not
T308A-S473A-Akt2, in which both threonine 308
and serine 473, critical residues for Akt activation,
were substituted into alanine. The levels of Akt
and TTC3 are shown in the lower panels.
(E) TTC3 expression was reduced by TTC3 siRNA
in a dose-dependent manner (top panel), which
was correlated inversely with phosphorylated Akt
levels (phospho-Thr308 and phospho-Ser473,
secondand thirdpanels fromthe top, respectively).
Increased phosphorylated Akt expression was
correlated with that of phosphorylation of FKHR
(forkhead transcriptional factor, sixth panel from
the top), without affecting the amount of total
FKHR (fifth panel from the top). TTC3 siRNA did
not affect the levels of MAPK (seventh and eighth
panels from the top). Control siRNA at the
maximumconcentration (64 nM) showed no effect.
(F) 293T cells were transfected with the indicated
plasmids (wild-type TTC3 with or without Myr-D-
PH-Akt [Kohn et al., 1996]) by the calcium phos-
phate method. Cells were treated with 17AAG
(Basso et al., 2002) for 12 hr before CHX treatment
(at time 0) with or without MG132. Wild-type TTC3
induced Akt degradation in a time-dependentmanner in the presence ofMyr-Akt, whichwas efficiently inhibited byMG132. Note thatMyr-Akt also showed a time-
dependent decrease in the absence of MG132 (second panel from top). Myr-Akt migrated at approximately 50KD on SDS-PAGE gel (also see Figure 4D).
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TTC3, an E3 Ligase for AktwithphosphorylatedAkt in the nucleus, andconcentrated around
the kinetochore during mitosis (Figures 5E and 5F). Addition of
MG132, a proteasomal inhibitor, enhanced the colocalization
of Ser473-phosphorylated Akt and Myr-Akt with endogenous
TTC3 (Figures S7 and S8). These results demonstrate that TTC3
preferentially colocalized with Akt in the nucleus throughout the
cell cycle.
Functional Interaction of Akt-TTC3 in DS Cells
Ubiquitination can regulate a wide variety of cellular functions
(Pickart and Eddins, 2004). Introduction of wild-type TTC3 signif-
icantly inhibited cell proliferation comparedwith S378A-TTC3- or
control-transfected cells (Figure 6A; also see Figure 4H). In
contrast, suppression of TTC3 by siRNA augmented cellular804 Developmental Cell 17, 800–810, December 15, 2009 ª2009 Elsproliferation in HT1080 and MCF7 cells (Figure 6B and data not
shown). Moreover, ectopic reintroduction of wild-type TTC3
clearly reverted or inhibited the augmented proliferation trig-
gered by the four different TTC3-siRNAs (Figure S9).
The gene for TTC3 is located within the DSCR (Antonarakis
et al., 2004), and is reported to be modestly overexpressed in
the tissues from DS individuals (Baldus et al., 2004). Ts65Dn,
a mouse model for DS, exhibits a 19% elevation of the TTC3
transcript and a demonstrated learning deficiency (Antonarakis
et al., 2004; Saran et al., 2003).
BothHs52.Skcells andCMK85cells (Satoet al., 1989),whichare
derived from DS individuals, showed increased TTC3 expression
with undetectable levels of phosphorylated Akt (Figure 6C). In
Hs52.Sk cells, TTC3 colocalized with Akt predominantly withinevier Inc.
Figure 4. Phosphorylation of TTC3 at
Ser378 Is Required for Efficient Biological
Function
(A) 293T cells were transfected with indicated
plasmids with or without Myr-Akt (cat. no.
21-151; Upstate Biotech). Akt activation efficiently
induced phosphorylation of wild-type TTC3 (top
panel, lane 5), but failed to phosphorylate
S378A-TTC3 by Myr-Akt. Note that, in the
absence of Myr-Akt (right panels), no phosphory-
lation of wild-type TTC3 was observed. The
expression of TTC3 after immunoprecipitation
(second panel from top) and phospho-Ser473Akt
(third panel from top) are also shown.
(B) In vitro Akt kinase assays were performed
using recombinant wild-type TTC3 and S378A-
TTC3. Akt efficiently phosphorylated wild-type
TTC3, but not S378A TTC3 (compare lanes 3 and
6, wild-type TTC3 and S378A TTC3, respectively).
Only Akt, but no other kinases, was present in this
assay, which supports the concept that Akt could
phosphorylate TTC3 at Ser378.
(C) We next performed an Akt-siRNA experiment
to suppress the endogenous expression of Akt.
The levels of the phosphorylation of TTC3
detected by anti-Akt substrate antibody (cat. no.
9611; Cell Signaling Technology) were diminished
in intensity, supporting the idea that endogenous
Akt phosphorylated TTC3 in the cellular context;
however, we cannot rule out that other kinases
might also be involved in vivo.
(D) 293T cells were transfected with wild-type
human TTC3, DRF-TTC3 (lacks C-terminal RING
finger domain), or S378A-TTC3 with pCGN-HA-
Ub (HA-tagged Ub). The results support that
S378 and RF of TTC3 were required for efficient
Akt ubiquitination. An equal amount of Akt expres-
sion after immunoprecipitation (middle panel,
lanes 1–4) and Flag-TTC3 (bottom panel) were
verified by immunoblot.
(E) TTC3 induced Akt degradation in the presence
of Myr-Akt to activate Akt (top panel, lanes 1–3
versus lanes 4–6, in the absence versus the
presence of Myr-Akt, respectively). In contrast,
S378A-TTC3 failed to induce Akt degradation
even in the presence of Myr-Akt.
(F) 293T cells were transfected with vector control,
wild-type TTC3, or S378A-TTC3 by the calcium
phosphate method. Using Rho123, TTC3 signifi-
cantly increased the high levels of the Rho123
staining cell population compared with S378A TTC3, wild-type TTC3, or control. Mean fluorescence intensities (MFIs) were 548, 162, and 379 for wild-type
TTC3, S378A TTC3, and control, respectively.
(G) In NFkB luciferase reporter assays (Stratagene), wild-type TTC3, but not S378A TTC3, failed to induce NFkB transactivation (relative activities were 2460 ±
330, 11,200 ± 860, and 4950 ± 380 for wild-type TTC3, S378A TTC3, and control, respectively). Statistical analysis was verified by Student’s t test, and error bars
represent SD (p < 0.05 considered as statistically significant).
(H) 293T cells were transfected with wild-type TTC3, S378A TTC3, or control. Wild-type TTC3 inhibited proliferative responses more efficiently than S378A TTC3
or control. Note that Myr-Akt efficiently reversed the inhibitory effects of TTC3 (see Figures S4A–S4C). Statistical analysis was verified by Student’s t test, and
error bars represent SD (p < 0.05 considered as statistically significant).
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TTC3, an E3 Ligase for Aktthe nucleus (see Figure 5G). Introduction of TTC3-siRNA into
CMK85 cells exhibited reduced TTC3 expression, which was cor-
related inversely with phosphorylated Akt expression (Figure 6D).
Consistent with the previous report that Akt activation is
known to overcome the G2M checkpoint (Kandel et al., 2002),
transfection of TTC3, which presumably facilitates proteasomal
degradation of Akt, exhibited an accumulation of cells at the
G2M checkpoint and a 70% decrease in G1:G2M (Figure 6E).DevelopmeSimilarly, introduction of TTC3 into HDF cells (Figure 6F) or
Jurkat cells (Figure 6G) also exhibited reduced G1:G2M ratio,
consistent with the result observed in 293T cells (see Figure 6E).
Analogous to this finding, both Hs52.Sk cells (Figure 6F, bottom
panel) and CMK85 cells (Figure 6G, bottom panel), with elevated
levels of TTC3 expression, exhibited a significant accumulation
of G2M cells, as detected by a relative decrease in the G1:G2M
ratio.ntal Cell 17, 800–810, December 15, 2009 ª2009 Elsevier Inc. 805
Figure 5. TTC3 Associates with Akt and
Induces Proteasomal Degradation of Akt
within the Nucleus
(A) 293T cells were transfected with wild-type
TTC3 and HA-Ub. Endogenous Akt (A) was
ubiquitinated more efficiently in the nucleus (N)
than in the cytoplasm (C) (compare lanes 7 and 8
[cytoplasmic and nuclear fractions, respectively]).
Please note that nuclear Akt was highly phosphor-
ylated compared with the cytoplasmic Akt (bottom
panel, lanes 4 and 8).
(B and C) 293T cells were transfected with wild-
type TTC3 and treated with 17AAG and CHX
(at time 0 for degradation assay) in the presence
or absence of MG132. Cells were then harvested
at the indicated time points, and cytoplasmic
and nuclear fractions were separated. TTC3
facilitated Akt degradation in the nucleus more
efficiently than in the cytoplasm (compare upper
panel, cytoplasmic fraction in lanes 1–3 versus
nuclear fraction in lanes 4–6, respectively).
MG132 treatment efficiently inhibited Akt degra-
dation (second panel from top). Times (hr) are
shown after CHX treatment (time 0). Relative
intensities were measured using NIH Image J (C).
Note that control transfected cells showed
minimal Akt degradation in the nuclear fraction
(data not shown).
(D) In NIH 3T3 cells, endogenous TTC3 (green)
colocalized with Akt (red) predominantly within
the nucleus during the interphase of the cell cycle,
as observed with confocal microscopy (top row).
Akt colocalized with TTC3 around the nuclear
membrane at prophase of themitotic cells (second
row, right panel, indicated by white arrowheads).
During the later period of the mitotic phase,
TTC3 and Akt became tightly colocalized with
each other around the kinetochore and midzone
of the cell.
(E and F) Furthermore, TTC3 (green) colocalized
with phosphorylated Akt (Ser473, red), both in
the interphase (E) and in the mitotic phase (F) of
the cell cycle.
(G) In Hs52.Sk cells from DS, in which TTC3 is
overexpressed (see Figure 6C), endogenous
TTC3 colocalized with Akt in the nucleus.
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TTC3, an E3 Ligase for AktIntroduction of TTC3-siRNA into CMK85 DS cells, which
enhanced the expression of phosphorylated Akt (see Figure 6D),
exhibited a 450% increase in the G1:G2M ratio (Figure 6H). In
contrast, CMK85 cells transfected with Myr-Akt overcame the
G2M phase, hence exhibiting a 300% increase of the G1:G2M
ratio (Figure 6I).
Together with the demonstration that TTC3 can enhance
apoptotic phenotypes (see Figures 4F–4H), these results further
support the functional significance of the TTC3-Akt interaction.
DISCUSSION
By means of a yeast two-hybrid screening, Akt was found to
interact specifically with TTC3, which is located within the
DSCR on human chromosome 21 (Antonarakis et al., 2004;806 Developmental Cell 17, 800–810, December 15, 2009 ª2009 ElsRachidi et al., 2000; Reeves et al., 2001; Tsukahara et al.,
1998). TTC3 is a 2025 amino acid protein, which is 76%
conserved between human and mice, and contains canonical
H2-RINGfinger domain consisting of a shortmotif rich in cysteine
and histidine residues (Hochstrasser, 2000; Pickart and Eddins,
2004).
By using immunoprecipitation and in vitro ubiquitination
assays, we confirmed that TTC3 interacted with Akt and
functions as a specific E3 ligase for Akt (Figure 7). The interaction
between Akt and TTC3 was mediated through the C-terminal
kinase domain of Akt. Since the kinase domain of Akt is highly
conserved (90%–95%) among the three Akt isoforms (Akt1,
Akt2, and Akt3), it is logical that TTC3 was able to interact with
all three isoforms of Akt. We show that AK1, another serine thre-
onine kinase, could not be ubiquitinated by TTC3. TTC3 is alsoevier Inc.
Figure 6. Functional Interaction of
Akt-TTC3 in Down Syndrome Cells
(A) Proliferation assays were performed and
analyzed by xCelligence (Real-Time Cell Analyzer;
Roche Applied Science). Wild-type TTC3 sig-
nificantly inhibited proliferative responses. The
results were consistent in three independent
experiments.
(B) HT1080 cells were treated with TTC3-siRNAs
or control scrambled RNA (IDT) by CUY21 Pro-
vitro (NEPA GENE Co,. Ltd). Proliferative
responses were enhanced by siRNA specific for
TTC3 (four different targeting siRNAs for TTC3,
designated as 1–4, indicated by closed triangles,
closed squares, ‘x’s, or closed circles, respec-
tively; see Supplemental Data) compared with
the control siRNA (indicated by open circles), as
analyzed by xCelligence (Real-TimeCell Analyzer).
(C) Hs52.Sk and CMK85 cells from DS, with high
endogenous TTC3 expression, exhibited inverse
correlations between TTC3 and phosphorylated
Akt at Thr308 expression.
(D) CMK85 cells were treated with the indicated
concentration of TTC3 siRNA or control siRNA
and analyzed using CUY21 Pro-vitro. TTC3 siRNA
reduced TTC3 expression (top panel), which was
inversely correlated with phosphorylated Akt at
Thr308 in a dose-dependent manner (middle gel
panel).
(E) 293Tcellswere transfectedwithTTC3or control
byPEI. TTC3suppressed theG2M-to-G1 transition;
hence, it increased the relative number of G2M
cells. Relative accumulation of cells in G2M-to-G1
transition shown by G1:G2M ratio was decreased
by 70% compared with control. Relative ratio of
G1:G2M is shown as a bar graph (E–I).
(F andG)Ectopic expressionof TTC3 intoHDFcells
(F) or Jurkat cells (G) suppressed the G1:G2M ratio
by over 70%, gated on the TTC3 (Flag)-positive
cell. Hs52.Sk or CMK85 cells, with high endoge-
nous TTC3 expression, showed a G1:G2M ratio
reduced by 80% compared with control cells.
(H) TTC3-siRNAor control siRNAwithpCMV-EGFP
were transfected into CMK85 cells. The cells were
fixed, stained with 7-AAD, and analyzed by FACS.
Introduction of TTC3-specific siRNA into CMK85
cells overcame theG2M phase; hence, an increase
in the G1:G2M ratio by more than 400% compared
with the control gated on the GFP-expressed cells.
(I) CMK85 cells were transfected with HA-tagged
Myr-Akt, fixed, and stained with anti-HA antibody
with 7-AAD. Introduction of Myr-Akt overcame
the G2M phase checkpoint transition; hence, it ex-
hibited more than a 300% increase in the G1:G2M
ratio gated on the Myr-Akt-expressed cells.
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TTC3, an E3 Ligase for Aktshown to inhibit neuronal differentiation via RhoA and citron
kinase (Berto et al., 2007). However, analogous to AK1 kinase,
TTC3 failed to induce ubiquitination of citron kinase and did
not degrade PDK (Figure S10 and data not shown).
In vitro ubiquitination assays demonstrated that Ubc4 and
Ubc5, as E2 enzymes, were required for TTC3-dependent
ubiquitination. The observation that either Ubc4 or Ubc5C was
required for TTC3-dependent ubiquitination is logical, since
Ubc4 and Ubc5C share 92% identity at the amino acid level.
The number of Ub-conjugating enzymes (known as E2) presentDevelopmein the human genome is approximately one-tenth that of the E3
ligases. Thus, it is possible that, in various cellular environments,
different combinations of E2s and E3s exhibit distinct functions
for their specific enzymatic targets.
Akt is known to be regulated primarily by phosphorylation at
two sites: a conserved threonine residue in the activation loop
(T308), and a serine/threonine residue in a hydrophobic motif
(S473) (Alessi et al., 1996; Brazil et al., 2004; Manning and
Cantley, 2007). Several lines of evidence have supported that
phosphorylation plays a key regulatory role in E3 functionntal Cell 17, 800–810, December 15, 2009 ª2009 Elsevier Inc. 807
Figure 7. TTC3 Is an E3 Ub Ligase for Akt
Akt, a core intracellular survival regulator, is known
to be activated at the plasma membrane and
subsequently translocalized to the nucleus.
However, little is known about the silencing
mechanisms of activated Akt after nuclear translo-
cation. Based on the current study, TTC3 is an E3
Ub ligase for Akt that preferentially binds to phos-
phorylated Akt, hence facilitating ubiquitination
and proteasomal degradation within the nucleus.
Since TTC3 is located within the DSCR of human
chromosome 21, the current study provides not
only the biological significance of the TTC3-Akt
functional interaction, but also a new insight into
the molecular mechanisms of DS, the most
common genetic disorder in humans.
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TTC3, an E3 Ligase for Akt(Gao and Karin, 2005; Hunter, 2007). To support this notion,
TTC3 interacted preferentially with phosphorylated Akt and
induced polyubiquitination and subsequent degradation of Akt
in the nucleus. Furthermore, PDGF stimulation, which induces
Akt activation, resulted in enhanced interaction between Akt
and TTC3, an Akt-specific Ub ligase.
Using Scansite (http://scansite.mit.edu/) (Obenauer et al.,
2003; Yaffe et al., 2001), Ser378 was identified as a putative
Akt phosphorylation site. This site was conserved in humans,
mice, and rats. Ser378 of TTC3 does not confirm the consensus
‘‘5 Arg’’ within the Akt phosphorylation motif (TPRSLSAP);
however, there were several molecules that were identified as
Akt substrates in which 5 Arg was not conserved, including
CREB (LSRRPS) (Kato et al., 2007) and SRPK2 (HDRSRT)
(Jang et al., 2009). In both cellular and in vitro assays, we showed
that wild-type TTC3, but not S378A, could be phosphorylated by
Akt. However, we cannot exclude that other kinases, such as
S6K and others, are able to phosphorylate TTC3 in vivo.
Functionally, this phosphorylation of TTC3 S378 was required
for all the activities that we identified for TTC3. In this regard, it is
of interest to define structurally how phosphorylated TTC3 and
phosphorylated Akt (preferentially on Thr305/308 of Akt) can
be interacted for a specific functional target.
TTC3 also contains a pair of nuclear localizing signals. Consis-
tently, TTC3 bound to Akt in a phosphorylation-dependent
manner, predominantly in the nucleus. Furthermore, by confocal
microscopy, we observed that endogenous TTC3 diffusely
distributed in the nucleus essentially throughout the cell cycle.
However, during the mitotic phase, TTC3 appeared to colocalize
with Akt at and around the kinetochore and the midzone of the
cell. This observation seems to be logical, since a pair of TPR
motifs present in TTC3 is suggested to play a role in mitotic
cell division (Lamb et al., 1995; Rachidi et al., 2000).
Recently, attention has been attracted to work demonstrating
the connection between ubiquitination-proteasomal pathways
and Akt signaling (Basso et al., 2002; Xiang et al., 2008).
Functional interactions of hsp90 with Akt for stabilizing Akt
have been reported. Chaperon-associated Ub ligase, a E3 ligase
family with a TPR motif, was shown to interact with hsp90 and808 Developmental Cell 17, 800–810, December 15, 2009 ª2009 Elscontrol the ubiquitination of Akt (Dickey et al., 2008; Ramsey
et al., 2000). Phosphorylation of Akt at the Turn motif (TM) is
also reported to control the stability of Akt (Facchinetti et al.,
2008). Based on coimmunoprecipiation and nuclear ubiquitina-
tion-degradation assays, TTC3 appeared to preferentially bind
phosphorylated Akt and target it for proteasomal degradation.
Since Akt activation enhanced the interaction between TTC3
and Akt, it is possible that Akt TM phosphorylation by mTORC2
will help to stabilize Akt and prevent TTC3-induced proteasomal
degradation.
The TTC3 gene is located within the DSCR, the trisomic locus
responsible for DS (Antonarakis et al., 2004). Individuals with DS
exhibit a wide variety of developmental abnormalities, including
mental retardation, characteristic facial and physical appear-
ances, congenital cardiac malformations, and a high frequency
of association with childhood leukemia (Reeves et al., 2001;
Sato et al., 1989; Shinohara et al., 2001).
Although dosage imbalance of the genes located within the
DSCR is believed to play a role in the molecular pathogenesis
of DS, due to the complexities of the clinical manifestation of
DS, the molecular mechanisms remain to be determined
(Antonarakis et al., 2004; Reeves et al., 2001). Increased TTC3
expression in the tissues derived from DS individual has also
been reported (Baldus et al., 2004; Saran et al., 2003). Nonchi-
meric polytransgenic 152F7 mice that express DSCR, DSCR5,
TTC3, and DYRK1A genes exhibited learning and memory
impairment. Another animal model for DS, Ts65Dn, in which
App-Znf295 of mouse genome is trisomic, also exhibited
a 19% elevation of TTC3 transcript (Antonarakis et al., 2004;
Reeves et al., 2001; Saran et al., 2003).
In DS-derived cells, we show decreased levels of phosphory-
lated Akt and relative accumulation of cells at the G2M phase
of the cell cycle. We demonstrate that TTC3 could enhance
an apoptotic phenotype and, inversely, that suppression of
TTC3 could enhance proliferation. Therefore, TTC3-Akt interac-
tion may explain the observation that increased apoptotic cells
appear in DS neurons with the generation of reactive oxygen
species, which is known to be regulated by Akt (Busciglio and
Yankner, 1995; reviewed by Manning and Cantley, 2007).evier Inc.
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TTC3, an E3 Ligase for AktThe tissue distribution of TTC3 is located predominantly in
neuronal cells (Rachidi et al., 2000; Tsukahara et al., 1998). DS
often exhibits subnormal brain development, with mental
retardation and a high incidence of onset of Alzheimer’s disease
at younger ages. Brain morphology in DS is characterized by
a reduced cortical size, a disproportionately small cerebellum,
and loss of cholinergic neurons (Reeves et al., 2001; Sato et al.,
1989; Shinohara et al., 2001). In this regard, it is of noteworthy
that Akt3-deficient mice exhibited a reduced brain size, affecting
all major brain regions, consistent with the restricted expression
of Akt3 in neurological tissues (Easton et al., 2005; Peng et al.,
2003; Tschopp et al., 2005). Although further studies are
required, our current work provides a possible clue for the
connection between altered interaction between TTC3 and Akt
and the development of clinical manifestations of DS, the most
common genetic disorder in humans.
EXPERIMENTAL PROCEDURES
Please refer to the detailed Supplemental Experimental Procedures.
Yeast Two-Hybrid Screening
Yeast two-hybrid assays were essentially performed as described previously
(Laine et al., 2000). Y190 cells (Clontech) were transformed by the lithium
acetate method with the ‘‘bait plasmid’’ (Akt2/PAS2-1). b-Gal-positive clones
were subsequently mated with Y187 yeast carrying pAS1-CYH2 without an
insert or with SNF-1 or p53 to determine the specificity for the interaction.
Construction of TTC3 Expression Vectors
Plasmid vector containing a partial cDNA fragment of human TTC3 was
purchased from imaGenes (RZPD). The 50 end of the cDNA of human TTC3
was extended by PCR amplification with cDNA from human peripheral blood
lymphocyte. The resultant PCR-amplified full-length TTC3 was subcloned
into the pCMV-Tag2 vector (Stratagene).
Cell Culture
293T cells (ATCC), NIH 3T3 cells (ATCC), f3 (normal skin fibroblast), HDF
(normal human dermal fibroblasts; cat. no. 106-05a; Cell Applications, Inc.),
or Hs52.Sk cells (DS patient-derived skin fibroblast, CRL-7031; ATCC) were
cultured in DMEM, and Jurkat cells (ATCC) or CMK85 cells (DS patient-derived
megakaryoblastic leukemia cells [Sato et al., 1989]) were cultured in RPMI
1640, both in the presence of 10% FBS and Pen/Strep at 37C with 5% CO2
unless otherwise specified.
Coimmunoprecipitation Experiments
Methods are essentially described by Laine et al. (2000) and are presented in
the Supplemental Data.
Generation and Purification of Recombinant TTC3
Methods are essentially described by Laine et al. (2000) and are presented in
the Supplemental Data.
Ubiquitination Assays
An in vitro ubiquitination assay was performed as previously described (Lorick
et al., 1999). Reaction mixtures with recombinant TTC3 were incubated for 2 hr
at 30C and immunoblotted. For the cellular ubiquitination experiments, cells
were transfected with the indicated TTC3 constructs or siRNA, treated with
MG132, and lysed, immunoprecipitated, and resolved onto SDS-PAGE and
immunoblotted.
siRNA
Cells were transfected with HA-Ub, treated with TTC3 siRNA (Invitrogen), and
immunoprecipitated with Akt and immunoblotted with anti-HA Abs. 293T cells
(ATCC) transfected with wild-type TTC3 were transfected with TTC3 siRNA or
control (IDT) by PEI, harvested, and immunoblotted with the indicatedDevelopmeantibodies. Hs52.Sk cells were transfected with Akt-siRNA (Cell Signaling
Technology) using CUY21 Pro-vitro (NEPA GENE Co., Ltd).
Myr-Akt-Induced Akt Degradation by TTC3
293T cells were transfected with the indicated plasmids with or without D-PH
Myr-Akt (Kohn et al., 1996). The cells were treated with 17-allylamino-17-
demethoxygeldanamycin (17AAG), an inhibitor for hsp90 (Basso et al.,
2002), for 12 hr before CHX treatment (at time 0), with or without MG132
(Sigma). Cells were harvested at the indicated time points, resolved onto
SDS-PAGE, and immunoblotted.
Brij97 Cell Lysis Buffer
The formulation of Brij buffer (Laine et al., 2000) is described in the
Supplemental Data.
Akt Induces Phosphorylation of S378
293T cells were transfected with the indicated plasmids with or without (as
indicated) Myr-Akt (cat. no. 21-151; Upstate Biotech). After 72 hr, the cells
were harvested, lysed, immunoprecipitated, resolved onto SDS-PAGE, and
immunoblotted using ECL.
Colocalization Experiment with Confocal Microscopy
NIH 3T3 cells or Hs52.Sk cells (ATCC) were cultured in DMEM with 10% FCS
with P/S, fixed with 3.7% formaldehyde, stained with the indicated antibodies
or DAPI (40,6-diamidino-2-phenylindole blue; Sigma), and examined by
confocal microscopy (Nikon).
Proliferation Assays with xCelligence
Proliferation assays were performed and analyzed by xCelligence (Real-Time
Cell Analyzer; Roche Applied Science) with 293T cells transfected with the
indicated plasmids (Figure 6A) by the PEI method, or siRNA-treated HT1080
cells by CUY21 Pro-vitro (NEPA GENE Co., Ltd) (Figure 6B).
Cell Cycle Analysis and Western Blot of DS Cells
Cells were transfected with the indicated expression vectors, harvested, fixed
with 70% ethanol, stained with anti-Flag or anti-HA antibody, Alexa 488
rebelled rabbit anti-mouse IgG, and 7-AAD, and analyzed (Figures 6C–6I).
Antibodies and siRNA
Antibodies and siRNA used in this study are listed in the Supplemental Data.
Statistical Analysis
Statistical analysis was verified by Student’s t test, and p < 0.05 was
considered as statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include ten figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.cell.com/
developmental-cell/supplemental/S1534-5807(09)00389-X.
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